Human-relevant 3D tissue modeling and AI-powered phenotypic screening services for pharmaceutical R&D
Purely Grow provides advanced preclinical screening services using the integrated ColFi3D™ and FibroAI™ platform.
Our system reconstructs physiologically relevant 3D human tissues and applies architectural AI analysis to improve translational predictability in drug development.
We help pharmaceutical partners identify failure earlier, rank compounds more accurately, and reduce late-stage attrition.
The Translational Challenge in Drug Development
Despite advances in molecular targeting and high-throughput screening:
- 90% of drug candidates fail in clinical trials
- 40–50% fail due to lack of efficacy
- 30% fail due to toxicity
- Phase I failures cost $200M–$500M per compound
A major driver of this failure is the use of simplified 2D cultures or non-physiological 3D systems that do not replicate native tissue architecture or vascular microenvironments.
Our Integrated Platform
ColFi3D™: Native Collagen 3D Tissue Models
- Insoluble native collagen fiber scaffolds
- Preserved mechanical stiffness
- Support for vascular-like structures
- Matrix-rich tumor microenvironment modeling
- Long-term tissue viability
FibroAI™: Architectural Phenotypic Intelligence
- Structural pattern recognition
- Vascular network mapping
- Tissue normalization scoring
- Early detection of therapeutic response
- AI-driven compound ranking
Together, these technologies provide deeper insight than traditional viability assays alone.
Service Offerings
1. Phenotypic Compound Screening
Evaluate compound libraries in physiologically relevant 3D tumor models.
Deliverables:
- Dose-response analysis
- Tissue normalization scores
- Architectural response profiles
- Compound ranking reports
2. Mechanism-of-Action Insights
Quantify how compounds influence:
- Matrix remodeling
- Vascular organization
- Structural tumor normalization
- Microenvironment interactions
3. Early Failure Detection
Identify:
- Ineffective compounds
- Toxic architectural disruption
- Off-target tissue damage
This allows prioritization decisions before costly in vivo or clinical stages.
4. Customized Tissue Models
We can tailor tissue systems to:
- Specific cancer subtypes
- Matrix stiffness conditions
- Microenvironment variations
- Patient-derived samples (collaborative studies)
Impact on R&D Economics
By improving preclinical prediction accuracy, our platform aims to:
- Reduce Phase I failure risk
- Improve compound prioritization
- Decrease reliance on animal models
- Accelerate time-to-decision
- Increase capital efficiency
Even marginal improvements in early screening accuracy can translate into hundreds of millions of dollars in downstream savings.
Partnership Models
We offer flexible engagement structures:
- Fee-for-service screening
- Strategic co-development partnerships
- Data-sharing collaborations
- Long-term discovery alliances
Our Vision for Pharma Collaboration
We believe the future of drug discovery requires:
- Human-relevant tissue models
- Matrix-aware phenotypic screening
- AI-powered architectural analysis
Purely Grow provides an integrated platform designed to strengthen translational reliability from preclinical testing to clinical outcomes.
For partnership inquiries or pilot project discussions, please contact Purely Grow.
